Expression of Akt Kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer

Pancreas

Volumn 43, Issue 7, 2014, Pages 1093-1100

  Ohtsubo, Koushiro ^a   Yamada, Tadaaki ^a   Zhao, Lu ^a   Jin, Tie Feng ^a   Takeuchi, Shinji ^a   Mouri, Hisatsugu ^a   Yamashita, Kaname ^a   Yasumoto, Kazuo ^a   Fujita, Naoya ^b   Kitagawa, Hirohisa ^a   Ohta, Tetsuo ^a   Ikeda, Hiroko ^a   Yano, Seiji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Akt kinase interacting protein 1; Pancreatic cancer; PI3K PDK1 Akt pathway; Scaffold protein

Indexed keywords

AKT1 PROTEIN, HUMAN; CC2D1A PROTEIN, HUMAN; DNA BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; SMALL INTERFERING RNA; TUMOR PROTEIN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VERY ELDERLY;

ADENOCARCINOMA; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; CELL DIVISION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84914168775     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000168     Document Type: Article

References (25)

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6:699-708.
2. Shaib YH, Davila JA, El-Serag HB. The epidemiology ofpancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther. 2006;24:87-94.
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
5. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
6. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640-1648.
7. Furukawa T. Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. J Gastroenterol. 2008;43:905-911.
8. Schlieman MG, Fahy BN, Ramsamooj R, et al. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer. 2003;89:2110-2115.
9. Asano T, Yao Y, Zhu J, et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004;23:8571-8580.
10. Bondar VM, Sweeney-Gotsch B, Andreeff M, et al. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002;1:989-997.
11. Ng SSW, Tsao MS, Chow S, et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000;60:5451-5455.
12. Duong HQ, Kim HJ, Kang HJ, et al. ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. Oncol Rep. 2012;27:182-188.
13. Dhanasekaran DN, Kashef K, Lee CM, et al. Scaffold proteins of MAP-kinase modules. Oncogene. 2007;26:3185-3202.
14. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-3310.
15. Nakamura A, Naito M, Tsuruo T, et al. Freud-1/Aki1, a novel PDK1-interacting protein, functions as a scaffold to activate the PDK1/Akt pathway in epidermal growth factor signaling. Mol Cell Biol. 2008;28:5996-6009.
16. Yamada T, Takeuchi S, Fujita N, et al. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene. 2013;32:4427-4435.
17. Genaral Rules for the Study of Pancreatic Cancer. 6th ed. Japan Pancreas Society; 2009.
18. Sobin LH, Gospodarowicz MK, Wittekind C, eds. UICC. TNM classification of malignant tumours. 7th ed. New York, NY: Wiley-Liss; 2009.
19. Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011;6:2011-2017.
20. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
21. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther. 2009;8:1095-1105.
22. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-518.
23. Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012;23:2834-2842.
24. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther. 2005;4:977-986.
25. Immervoll H, Hoem D, Kugarajh K, et al. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448:788-796.